NDAC
This article was originally published in The Tan Sheet
Executive Summary
Meeting scheduled Dec. 1 for the discussion of an NDA. The Sept. 10 meeting scheduled for the discussion of an NDA has been canceled, along with tentatively scheduled dates of Oct. 29-30. Possible candidates for discussion at the December meeting include SmithKline Beecham's Denavir for cold sores or McNeil's Nicotrol NS nasal spray or Nicotrol inhaler. On Sept. 11, the committee is meeting at 8:30 a.m. at the Holiday Inn in Bethesda, Md. to discuss class labeling for OTC vaginal antifungal drug products, for which the agency issued a guidance July 16 ("The Tan Sheet" July 20, p. 5). The committee's discussion of pediatric labeling for combination drug products has been postponed. NDAC's Dental Plaque Subcommittee is scheduled to meet Oct. 22-23 and Dec. 2-3 for a continuing discussion of issues related to the development of a monograph for OTC gingivitis/plaque products...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning